CD-388 is under clinical development by and currently in Phase I for Influenzavirus B Infections. According to GlobalData, Phase I drugs for Influenzavirus B Infections have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CD-388’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CD-388 overview
CD-388 is under development for the treatment and prevention of influenzavirus A, seasonal influenza, pandemic influenza and influenzavirus B infections. The drug candidate is a second generation, anti-viral Fc conjugate (AVC). It comprises of two moieties attached through a chemical linker. One is a targeting moiety (TM) that recognizes cell surface target (neuraminidase) and another is an effector moiety (EM) that is recognized by the immune system. The drug candidate is developed based on the cloudbreak platform. It is administered through intramuscular and subcutaneous route in the form of liquid.
Cidara Therapeutics overview
(Cidara) is a biotechnology company. The company discovers, develops and commercializes novel anti-infectives including immunotherapies. Its pipeline products include rezafungin for the treatment of invasive fungal disease and cloudbreak-
For a complete picture of CD-388’s drug-specific PTSR and LoA scores,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
